Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2003

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2003

The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond

Por Petrylak, Daniel P
Publicado em 2006

New Paradigms for Advanced Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2007

New developments in the treatment of castration resistant prostate cancer

Por Wadia, Roxanne, Petrylak, Daniel P
Publicado em 2014

Immune Analysis of Radium-223 in Patients with Metastatic Prostate Cancer

Por Kim, Joseph W., Shin, Min Sun, Kang, Youna, Kang, Insoo, Petrylak, Daniel P
Publicado no Clin Genitourin Cancer (2017)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

Por Crawford, E. David, Shore, Neal D., Petrylak, Daniel P., Higano, Celestia S., Ryan, Charles J.
Publicado no Ther Adv Med Oncol (2017)

Prostate Cancer Update: Advanced Disease

Por Carducci, Michael A, Crawford, E. David, Higano, Celestia S, Mendoza-Valdes, Arturo, Petrylak, Daniel P, Schalken, Jack
Publicado em 2003

Hormone-Refractory Prostate Cancer: New Horizons

Por Petrylak, Daniel P, Abrahamsson, Per-Anders, Bartsch, Georg, Carducci, Michael A, Small, Eric J, Wilding, George
Publicado em 2003

Androgen Deprivation and Other Treatments for Advanced Prostate Cancer

Por Brawer, Michael K, Crawford, E David, Labrie, Fernand, Mendoza-Valdes, Arturo, Miller, Paul D, Petrylak, Daniel P
Publicado em 2001

Therapeutic Strategies for Localized Prostate Cancer

Por Lynch, John H, Batuello, Joseph T, Crawford, E David, Gomella, Leonard G, Kaufman, Joel, Petrylak, Daniel P, Joel, Andrew B
Publicado em 2001

Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non–muscle-invasive Bladder Cancer Refractory to Standard Intravesical Therapy

Por Laudano, Melissa A., Barlow, Lamont J., Murphy, Alana M., Petrylak, Daniel P., Desai, Manisha, Benson, Mitchell C., McKiernan, James M.
Publicado no Urology (2009)

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

Por Armstrong, Andrew J., Eisenberger, Mario A., Halabi, Susan, Oudard, Stephane, Nanus, David M., Petrylak, Daniel P., Sartor, A. Oliver, Scher, Howard I.
Publicado em 2011

GEMCITABINE AND CISPLATIN IN UNRESECTABLE MALIGNANT MESOTHELIOMA OF THE PLEURA: A PHASE II STUDY OF THE SOUTHWEST ONCOLOGY GROUP (SWOG 9810)

Por Kalmadi, Sujith R., Rankin, Cathryn, Kraut, Michael J., Jacobs, Andrew D., Petrylak, Daniel P., Adelstein, David J., Keohan, Mary Louise, Taub, Robert N., Borden, Ernest C.
Publicado em 2007

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RAN...

Por Necchi, Andrea, Nishiyama, Hiroyuki, Matsubara, Nobuaki, Lee, Jae-Lyun, Petrylak, Daniel P., de Wit, Ronald, Drakaki, Alexandra, Liepa, Astra M., Mao, Huzhang, Bell-McGuinn, Katherine, Powles, Thomas
Publicado no BMC Urol (2020)

A Double Blind Randomized Crossover Study of Oral Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation

Por Figg, William D., Hussain, Maha H., Gulley, James L., Arlen, Philip M., Aragon-Ching, Jeanny B., Petrylak, Daniel P., Higano, Celestia S., Steinberg, Seth M., Sartor, Oliver, Dahut, William L.
Publicado em 2009

Cooperative group trials – Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Por Dorff, Tanya B., Tangen, Cathy M., Crawford, E. David, Petrylak, Daniel P., Higano, Celestia S., Raghavan, Derek, Quinn, David I., Vogelzang, Nicholas J., Thompson, Ian M., Hussain, Maha H.A.
Publicado em 2009

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Gué...

Por Skinner, Eila C., Goldman, Bryan, Sakr, Wael A., Petrylak, Daniel P., Lenz, Heinz-Josef, Lee, Cheryl T., Wilson, Shandra S., Benson, Mitchell, Lerner, Seth P., Tangen, Cathy M., Thompson, Ian M.
Publicado em 2013

Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients with Locally Advanced Carcinoma of the Bladder

Por Smith, David C., Mackler, Niklas J, Dunn, Rodney L., Hussain, Maha, Wood, David, Lee, Cheryl T., Sanda, Martin, Vaishampayan, Ulka, Petrylak, Daniel P., Quinn, David I., Beekman, Kathleen, Montie, James E.
Publicado em 2008

KINETICS OF SERUM ANDROGEN NORMALIZATION AND FACTORS ASSOCIATED WITH TESTOSTERONE RESERVE AFTER LIMITED ANDROGEN-DEPRIVATION THERAPY IN NONMETASTATIC PROSTATE CANCER

Por Gulley, James L., Aragon-Ching, Jeanny B., Steinberg, Seth M., Hussain, Maha H., Sartor, Oliver, Higano, Celestia S., Petrylak, Daniel P., Chatta, Gurkamal S., Arlen, Philip M., Figg, William D., Dahut, William L.
Publicado em 2008